According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...

In a recent review published in Genes & Diseases, researchers from Jinzhou Medical University, Technische Universität Dresden, and Helmholtz-Zentrum ...

Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study. The results could potentially lead to new therapies ...

Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its 2026 corporate outlook and highlight 2025 milestones centered on its lead ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for ...

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of ...